Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?

This article was originally published in The Pink Sheet Daily

Executive Summary

Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.

You may also be interested in...

Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say

It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience

AstraZeneca: Aspirin May Be To Blame For Poor Results In Some Brilinta Trial Patients

Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts